BioSpace News Archive

Axonics Modulation Technologies, Inc., a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation devices for the treatment of urinary and bowel dysfunction, has reported full 2-year clinical results from its ARTISAN-SNM pivotal study.

Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced the appointment of William H. Carson, M.D., to its Board of Directors. “Bill knows how to drive the development of innovative treatments — including drugs for a wide range of diseases that affect the brain — from concept to commercialization,” said Franc

- Investigational New Drug (IND) application was authorized to proceed by the US FDA for human dosing with oral zavegepant - Biohaven achieved first in human dosing with oral zavegepant to assess the safety and pharmacokinetic profile - Zavegepant is a third generation, high affinity, selective and structurally unique, small molecule CGRP receptor antagonist in development for both migraine and non-migraine indications including COVID-19 associated lung inflammation

ESSA Pharma Inc. (Nasdaq: EPIX; TSX-V: EPI; ) (“ESSA” or the “Company”), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer announced the Company will be presenting at the H.C. Wainwright 22 nd Annual Global Investment Conference o

Korro’s OPERA platform harnesses the body’s natural base editing machinery to program precise, single-base RNA edits to treat disease

Exicure, Inc. (Nasdaq: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, today announced presentations at the following conferences during the month of September: TIDES: Oligonucleotide & Peptide Therapeutics Panel discussion: The impact of technological advances in the TIDES Space Presented by: CEO David Giljohann Tue

-Engaging with patient community and presenting overview of PRESIDIO study at The Myositis Association’s (TMA) International Annual Patient Conference -Scientific poster presentation on MISSION Phase 1b study data at 22 nd Pan-American Congress of Rheumatology 2020 (PANLAR 2020)

- Enrollment initiated in Phase 1 MAD study in patients with high-risk genetic variants for dry AMD – - Phase 1 topline results demonstrate promising safety profile, with no treatment-related adverse events as well as PK and biomarker changes in genetically defined dry AMD - CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Gemini Therapeutics, a clinical stage precision medicine company developing innovative treatments for genetically defined Age-

CooperCompanies announced that the company, along with its CooperVision and CooperSurgical divisions has been named one of Fortune’s Best Large Workplaces in Manufacturing and Production.

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Zynerba’s Chief Executive Officer, Armando Anido will participate in two upcoming virtual investor conferences. Mr. Anido will present a company overview at the HC Wainwright Virtual 22 nd Annual Healthcare Conference on Monday September 14, 2020 a